Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Nanomedicines in the treatment of brain tumors.

Fisusi FA, Schätzlein AG, Uchegbu IF.

Nanomedicine (Lond). 2018 Mar;13(6):579-583. doi: 10.2217/nnm-2017-0378. Epub 2018 Jan 29. No abstract available.

2.

Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia.

Godfrey L, Iannitelli A, Garrett NL, Moger J, Imbert I, King T, Porreca F, Soundararajan R, Lalatsa A, Schätzlein AG, Uchegbu IF.

J Control Release. 2018 Jan 28;270:135-144. doi: 10.1016/j.jconrel.2017.11.041. Epub 2017 Nov 27.

3.

T-shaped Peptide Amphiphiles Self Assemble into Nanofiber Networks.

Fisusi FA, Notman R, Granger LA, Malkinson JP, Schatzlein AG, Uchegbu IF.

Pharm Nanotechnol. 2017;5(3):215-219. doi: 10.2174/2211738505666170828095937.

PMID:
28847269
4.

Limiting the level of tertiary amines on polyamines leads to biocompatible nucleic acid vectors.

Simão Carlos MI, Zheng K, Garrett N, Arifin N, Workman DG, Kubajewska I, Halwani AA, Moger J, Zhang Q, Schätzlein AG, Uchegbu IF.

Int J Pharm. 2017 Jun 30;526(1-2):106-124. doi: 10.1016/j.ijpharm.2017.04.059. Epub 2017 Apr 25.

PMID:
28450169
5.

Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.

Fisusi FA, Siew A, Chooi KW, Okubanjo O, Garrett N, Lalatsa K, Serrano D, Summers I, Moger J, Stapleton P, Satchi-Fainaro R, Schätzlein AG, Uchegbu IF.

Pharm Res. 2016 May;33(5):1289-303. doi: 10.1007/s11095-016-1872-x. Epub 2016 Feb 22.

6.

Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles.

Serrano DR, Lalatsa A, Dea-Ayuela MA, Bilbao-Ramos PE, Garrett NL, Moger J, Guarro J, Capilla J, Ballesteros MP, Schätzlein AG, Bolás F, Torrado JJ, Uchegbu IF.

Mol Pharm. 2015 Feb 2;12(2):420-31. doi: 10.1021/mp500527x. Epub 2015 Jan 15.

PMID:
25558881
7.

Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration.

Lalatsa A, Schätzlein AG, Garrett NL, Moger J, Briggs M, Godfrey L, Iannitelli A, Freeman J, Uchegbu IF.

J Control Release. 2015 Jan 10;197:87-96. doi: 10.1016/j.jconrel.2014.10.028. Epub 2014 Nov 5.

8.

Physical characterisation and long-term stability studies on quaternary ammonium palmitoyl glycol chitosan (GCPQ)--a new drug delivery polymer.

Chooi KW, Simão Carlos MI, Soundararajan R, Gaisford S, Arifin N, Schätzlein AG, Uchegbu IF.

J Pharm Sci. 2014 Aug;103(8):2296-306. doi: 10.1002/jps.24026. Epub 2014 Jun 10.

PMID:
24916193
9.

Optimisation of synthetic vector systems for cancer gene therapy - the role of the excess of cationic dendrimer under physiological conditions.

Santander-Ortega MJ, de la Fuente M, Lozano MV, Tsui ML, Bolton K, Uchegbu IF, Schätzlein AG.

Curr Top Med Chem. 2014;14(9):1172-81.

PMID:
24678705
10.

Strategies to deliver peptide drugs to the brain.

Lalatsa A, Schatzlein AG, Uchegbu IF.

Mol Pharm. 2014 Apr 7;11(4):1081-93. doi: 10.1021/mp400680d. Epub 2014 Mar 21. Review.

PMID:
24601686
11.

Dextran-pegylated microparticles for enhanced cellular uptake of hydrophobic drugs.

Cassano R, Ferrarelli T, Schätzlein AG, Uchegbu IF, Trombino S.

Eur J Pharm Biopharm. 2013 Aug;84(3):540-8. doi: 10.1016/j.ejpb.2013.01.017. Epub 2013 Feb 16.

PMID:
23419813
12.

Nanofiber-based delivery of therapeutic peptides to the brain.

Mazza M, Notman R, Anwar J, Rodger A, Hicks M, Parkinson G, McCarthy D, Daviter T, Moger J, Garrett N, Mead T, Briggs M, Schätzlein AG, Uchegbu IF.

ACS Nano. 2013 Feb 26;7(2):1016-26. doi: 10.1021/nn305193d. Epub 2013 Jan 10.

PMID:
23289352
13.

Amphiphilic poly(L-amino acids) - new materials for drug delivery.

Lalatsa A, Schätzlein AG, Mazza M, Le TB, Uchegbu IF.

J Control Release. 2012 Jul 20;161(2):523-36. doi: 10.1016/j.jconrel.2012.04.046. Epub 2012 May 18. Review.

PMID:
22613882
14.

A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain.

Lalatsa A, Lee V, Malkinson JP, Zloh M, Schätzlein AG, Uchegbu IF.

Mol Pharm. 2012 Jun 4;9(6):1665-80. doi: 10.1021/mp300009u. Epub 2012 May 18.

PMID:
22574705
15.

Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles.

Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schätzlein AG, Uchegbu IF.

Mol Pharm. 2012 Jun 4;9(6):1764-74. doi: 10.1021/mp300068j. Epub 2012 May 21.

PMID:
22571402
16.

Polyamine aza-cyclic compounds demonstrate anti-proliferative activity in vitro but fail to control tumour growth in vivo.

Wong PE, Tetley L, Dufès C, Chooi KW, Bolton K, Schätzlein AG, Uchegbu IF.

J Pharm Sci. 2010 Nov;99(11):4642-57. doi: 10.1002/jps.22165.

PMID:
20845462
17.

In silico modelling of drug-polymer interactions for pharmaceutical formulations.

Ahmad S, Johnston BF, Mackay SP, Schatzlein AG, Gellert P, Sengupta D, Uchegbu IF.

J R Soc Interface. 2010 Aug 6;7 Suppl 4:S423-33. doi: 10.1098/rsif.2010.0190.focus. Epub 2010 Jun 2.

18.

Cancer-specific transgene expression mediated by systemic injection of nanoparticles.

Chisholm EJ, Vassaux G, Martin-Duque P, Chevre R, Lambert O, Pitard B, Merron A, Weeks M, Burnet J, Peerlinck I, Dai MS, Alusi G, Mather SJ, Bolton K, Uchegbu IF, Schatzlein AG, Baril P.

Cancer Res. 2009 Mar 15;69(6):2655-62. doi: 10.1158/0008-5472.CAN-08-2657. Epub 2009 Mar 3.

19.

Cancer and the blood-brain barrier: 'Trojan horses' for courses?

Mazza M, Uchegbu IF, Schätzlein AG.

Br J Pharmacol. 2008 Sep;155(2):149-51. doi: 10.1038/bjp.2008.274. Epub 2008 Jun 30.

20.

High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil.

Holmes WM, Maclellan S, Condon B, Dufès C, Evans TR, Uchegbu IF, Schätzlein AG.

Phys Med Biol. 2008 Jan 21;53(2):505-13. doi: 10.1088/0031-9155/53/2/015. Epub 2007 Dec 28.

PMID:
18185002
21.

A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo.

Bell HS, Dufes C, O'Prey J, Crighton D, Bergamaschi D, Lu X, Schätzlein AG, Vousden KH, Ryan KM.

J Clin Invest. 2007 Apr;117(4):1008-18. Epub 2007 Mar 8.

22.

Delivering cancer stem cell therapies - a role for nanomedicines?

Schätzlein AG.

Eur J Cancer. 2006 Jun;42(9):1309-15. Epub 2006 May 8. Review.

PMID:
16682183
23.

Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds.

Cheng WP, Gray AI, Tetley L, Hang Tle B, Schätzlein AG, Uchegbu IF.

Biomacromolecules. 2006 May;7(5):1509-20.

PMID:
16677033
24.

Dendrimers in gene delivery.

Dufès C, Uchegbu IF, Schätzlein AG.

Adv Drug Deliv Rev. 2005 Dec 14;57(15):2177-202. Epub 2005 Nov 28. Review.

PMID:
16310284
25.

Tumour gene expression from C12 spermine amphiphile gene delivery systems.

Kan PL, Gray AI, Tetley L, Converse CA, Schätzlein AG, Uchegbu IF.

J Drug Target. 2005 Jul;13(6):345-57.

PMID:
16278154
26.

Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.

Dufès C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schätzlein AG.

Cancer Res. 2005 Sep 15;65(18):8079-84.

27.

Gene transfer with three amphiphilic glycol chitosans--the degree of polymerisation is the main controller of transfection efficiency.

Uchegbu IF, Sadiq L, Pardakhty A, El-Hammadi M, Gray AI, Tetley L, Wang W, Zinselmeyer BH, Schätzlein AG.

J Drug Target. 2004;12(8):527-39.

PMID:
15621678
28.

Preferential liver gene expression with polypropylenimine dendrimers.

Schatzlein AG, Zinselmeyer BH, Elouzi A, Dufes C, Chim YT, Roberts CJ, Davies MC, Munro A, Gray AI, Uchegbu IF.

J Control Release. 2005 Jan 3;101(1-3):247-58.

PMID:
15588909
29.

Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain.

Dufes C, Gaillard F, Uchegbu IF, Schätzlein AG, Olivier JC, Muller JM.

Int J Pharm. 2004 Nov 5;285(1-2):77-85.

PMID:
15488681
30.

Tumour-targeted drug and gene delivery: principles and concepts.

Cassidy J, Schätzlein AG.

Expert Rev Mol Med. 2004 Sep 13;6(19):1-17. Review.

PMID:
15387893
31.

PEI-based vesicle-polymer hybrid gene delivery system with improved biocompatibility.

Brownlie A, Uchegbu IF, Schätzlein AG.

Int J Pharm. 2004 Apr 15;274(1-2):41-52.

PMID:
15072781
32.

Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor.

Hollins AJ, Benboubetra M, Omidi Y, Zinselmeyer BH, Schatzlein AG, Uchegbu IF, Akhtar S.

Pharm Res. 2004 Mar;21(3):458-66.

PMID:
15070097
33.

Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.

Dufes C, Muller JM, Couet W, Olivier JC, Uchegbu IF, Schätzlein AG.

Pharm Res. 2004 Jan;21(1):101-7.

PMID:
14984263
34.

In vitro and in vivo gene transfer with poly(amino acid) vesicles.

Brown MD, Gray AI, Tetley L, Santovena A, Rene J, Schätzlein AG, Uchegbu IF.

J Control Release. 2003 Dec 5;93(2):193-211.

PMID:
14636725
35.

Quantification of beta-galactosidase activity after non-viral transfection in vivo.

Zinselmeyer BH, Beggbie N, Uchegbu IF, Schätzlein AG.

J Control Release. 2003 Aug 28;91(1-2):201-8.

PMID:
12932652
36.

Targeting of Synthetic Gene Delivery Systems.

Schätzlein AG.

J Biomed Biotechnol. 2003;2003(2):149-158.

37.

The lower-generation polypropylenimine dendrimers are effective gene-transfer agents.

Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF.

Pharm Res. 2002 Jul;19(7):960-7.

PMID:
12180548
38.

Solid-phase synthesis of c(RGDfK) derivatives: on-resin cyclisation and lysine functionalisation.

McCusker CF, Kocienski PJ, Boyle FT, Schätzlein AG.

Bioorg Med Chem Lett. 2002 Feb 25;12(4):547-9.

PMID:
11844669
39.

Gene delivery with synthetic (non viral) carriers.

Brown MD, Schätzlein AG, Uchegbu IF.

Int J Pharm. 2001 Oct 23;229(1-2):1-21. Review.

PMID:
11604253
40.

Phage derived peptides for targeting of doxorubicin conjugates to solid tumours.

Schatzlein AG, Rutherford C, Corrihons F, Moore BD.

J Control Release. 2001 Jul 6;74(1-3):357-62.

PMID:
11489518
41.

Quaternary ammonium palmitoyl glycol chitosan--a new polysoap for drug delivery.

Uchegbu IF, Sadiq L, Arastoo M, Gray AI, Wang W, Waigh RD, Schätzlein AG.

Int J Pharm. 2001 Aug 14;224(1-2):185-99. Erratum in: Int J Pharm 2001 Nov 6;230(1-2):77. Schätzleinä AG [corrected to Schätzlein AG].

PMID:
11472828
42.

Non-viral vectors in cancer gene therapy: principles and progress.

Schatzlein AG.

Anticancer Drugs. 2001 Apr;12(4):275-304. Review.

PMID:
11335785
43.

Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting.

Dufes C, Schätzlein AG, Tetley L, Gray AI, Watson DG, Olivier JC, Couet W, Uchegbu IF.

Pharm Res. 2000 Oct;17(10):1250-8.

PMID:
11145231
44.

The encapsulation of bleomycin within chitosan based polymeric vesicles does not alter its biodistribution.

Sludden J, Uchegbu IF, Schätzlein AG.

J Pharm Pharmacol. 2000 Apr;52(4):377-82.

PMID:
10813546
45.

Polymeric chitosan-based vesicles for drug delivery.

Uchegbu IF, Schätzlein AG, Tetley L, Gray AI, Sludden J, Siddique S, Mosha E.

J Pharm Pharmacol. 1998 May;50(5):453-8.

PMID:
9643437

Supplemental Content

Loading ...
Support Center